Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansa Biopharma AB ( (SE:HNSA) ) has provided an update.
Hansa Biopharma announced that its Phase 3 trial for the treatment of anti-glomerular basement membrane (anti-GBM) disease with imlifidase did not meet its primary endpoint of improving renal function. Despite this, the trial showed that 60% of patients treated with imlifidase and standard care did not require dialysis at six months, a significant improvement over historical outcomes. The trial’s results highlight the potential benefits of aggressive treatment for anti-GBM patients, though the imlifidase treatment did not achieve statistically significant results. The company remains optimistic about imlifidase’s potential in other areas, such as gene therapy and kidney transplantation.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme.
Average Trading Volume: 742,523
Technical Sentiment Signal: Hold
Current Market Cap: SEK3.65B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.